Background Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer eff ects in preclinical and clinical studies. We aimed to establish whether bisphosphonates can aff ect clinical outcomes in patients with multiple myeloma.
Introduction
Myeloma is a plasma-cell malignant disease that can result in osteolytic lesions, excess immunoglobulin secretion, impaired renal function, and myelosuppression. 1 Myeloma plasma cells live in the bone marrow microenvironment 1, 2 and can secrete factors that stimulate osteoclast-mediated osteolysis, 2 placing patients at risk for skeletal-related events such as fractures and bone pain requiring pallia tive radiotherapy. 3 Bisphosphonates were developed mainly to impair malignant osteolysis, thereby breaking the cycle of bone destruction and cancer growth that can result in skeletal-related events. 4 By blocking growth-factor release from the bone matrix, bisphosphonates can indirectly impede myeloma growth. 5 Preclinical evidence suggests that bisphosphonates-especially nitrogencontaining bisphosphonates such as zoledronic acidmight have inherent anticancer activities. 4, 6 Moreover, zoledronic acid signifi cantly extended survival in two mouse models of multiple myeloma. 7, 8 The antimyeloma eff ect was independent of the eff ect of zoledronic acid on bone, but dependent on inhibition of protein prenylation, 8 a mechanism of action not shared by non-nitrogen-containing bisphosphonates such as clodronic acid (clodronate). 4 Although diff erences in overall survival with bisphosphonates were not signifi cant in the full populations of large randomised controlled trials in multiple myeloma, [9] [10] [11] [12] bisphosphonates seemed to improve overall survival in subsets of patients in phase 3 studies. [9] [10] [11] For example, in the UK Medical Research Council (MRC) trial in patients with bone lesions from multiple myeloma (n=535), overall survival was similar between clodronic acid and placebo in the full population, but clodronic acid signifi cantly improved overall survival versus placebo in the subset of patients who had not had fractures before study entry (n=153; p=0·006). 11 Furthermore, in large-scale randomised trials in patients undergoing adjuvant endocrine therapy for early breast cancer, zoledronic acid signifi cantly extended diseasefree survival (n=1803 and n=1065), 13, 14 and clodronic acid extended overall survival in patients with metastatic prostate cancer (n=278). 15 Moreover, zoledronic acid showed anticancer synergy with some chemotherapy agents in preclinical assays. 6 Therefore, bisphosphonates might aff ect the disease course of multiple myeloma.
Despite strong consensus that antimyeloma therapies should be given to symptomatic patients with multiple myeloma, 16, 17 no optimal regimen has emerged. Therefore, we designed the MRC Myeloma IX trial, an innovative study with two randomisation steps to allow comparison of both fi rst-line and maintenance treatments for adult patients with newly diagnosed multiple myeloma. The fi rst randomisation step compared oral clodronic acid and an intravenous bisphosphonate with respect to overall survival, progression-free survival, response rates, and skeletal-related events. Of the two intravenous bisphosphonates approved for prevention of skeletalrelated events in multiple myeloma, pamidronic acid (pamidronate) and zoledronic acid, we selected zoledronic acid because it has higher antiresorbtive activity and shorter infusion time than does pamidronic acid. 4, 12 
Methods

Patients
In the MRC Myeloma IX trial, adult patients of age 18 years or older who had newly diagnosed and histologically confi rmed symptomatic multiple myeloma were enrolled from 120 centres in the UK. Patients were excluded if they had previous or concurrent active malignancies, had acute renal failure (serum creatinine >500 μmol/L and unresponsive to 72 h of rehydration, urine output <400 mL/day, or need for dialysis), had previously received treatment for myeloma (apart from local radiotherapy, bisphosphonates, or low-dose corticosteroids), or were pregnant or lactating. A strict risk-management programme was adopted, and all patients who were women of childbearing potential, or were men engaging in heterosexual activity with a woman of childbearing potential, had to use contraception.
The trial was approved by the North West Multi-centre Research Ethics Committee, and by local review committees at all participating centres. All patients provided written informed consent.
Randomisation and masking
The Clinical Trials Research Unit of the University of Leeds, Leeds, UK, used a computer-generated randomisation sequence to assign treatment groups via an automated telephone service. The trial had a two-by-two factorial design, with two randomisation steps and equal allocation to two groups at each randomisation step. The fi rst randomisation step compared fi rst-line treatments, and the second compared maintenance treatments. The fi rst randomisation used a minimisa tion algorithm stratifi ed by centre, haemoglobin (<115 vs ≥115 g/L for men, <95 vs ≥95 g/L for women), serum calcium (<2·6 vs ≥2·6 mmol/L; corrected for serum albumin), serum creatinine (<140 vs ≥140 μmol/L), and platelet count (<150×10⁹/L or ≥150×10⁹/L). The maintenance randomisation used a minimisation algorithm stratifi ed by centre and treatment group allocated at fi rst randomisation. In this open-label trial, no investigators, staff at participating centres, or patients were masked to treatment allocation apart from individuals analysing treatment response from laboratory results.
Procedures
Before randomisation, patients were allocated to receive induction chemotherapy via one of two pathways, intensive and non-intensive. Pathway selection had no rigid age cutoff and was based on performance status, clinician judgment, and patient preference. The intensive pathway consisted of four-six 21-day cycles of either CVAD (500 mg oral cyclophosphamide per week, 0·4 mg vincristine daily combined with 9 mg/m² doxorubicin Figure 1 : Trial profi le *Patients were included in the safety population. †Two patients on zoledronic acid received a conditioning regimen other than high-dose melphalan and underwent subsequent autologous stem-cell transplantation. ‡One patient in the non-intensive pathway who was excluded because no consent was received was then included in the randomisation to receive maintenance treatment; some of the 23 patients in the intensive pathway who did not start CVAD or CTD did receive high-dose melphalan plus autologous stem-cell transplantation, but none was included in the randomisation to receive maintenance treatment; none of the 12 patients in the non-intensive pathway who did not start MP or CTDa was included in the randomisation to receive maintenance treatment. CVAD=cyclophosphamide, vincristine, doxorubicin, and dexamethasone. CTD=cyclophosphamide, thalidomide, and dexamethasone. MP=melphalan and prednisolone. CTDa=attenuated CTD. BD=bortezomib and dexamethasone. In the fi rst randomisation, patients in the intensive pathway were allocated to receive either clodronic acid or zoledronic acid plus induction chemotherapy with either CVAD or CTD, and patients in the non-intensive pathway were allocated to receive either clodronic acid or zoledronic acid plus induction chemotherapy with either MP or CTDa. Clodronic acid was given at a dose of 1600 mg per day orally, and zoledronic acid at a dose of 4 mg as a 15-min infusion every 3-4 weeks during induction chemotherapy and every 4 weeks thereafter. The dose of zoledronic acid was adjusted for patients with impaired renal function at baseline, and was delayed in patients with raised creatinine concentrations during the study, as per the prescribing information. After fi rst-line therapy (about 100 days after autologous stem-cell transplantation in the intensive pathway), the second randomisation allocated eligible patients (no disease progression, and opted to continue study treatment according to the protocol) to receive either maintenance therapy with 50 mg thalidomide daily and increasing to 100 mg daily if tolerated, or no further treatment. Bisphosphonates and main tenance therapy were given continuously at least until disease progression.
We followed the recommendations of Weitzman and colleagues 18 to reduce the risk of osteonecrosis of the jaw and to identify and manage such cases. 18 All suspected cases of osteonecrosis of the jaw were referred to a dental professional for diagnosis and management, and reports were centrally reviewed by an investigator.
The primary endpoints were overall survival, progression-free survival, and overall response rate. Secondary endpoints included skeletal-related events and toxic eff ects. Overall survival and progression-free survival were calculated from fi rst randomisation to death or to progression or death, respectively. Patients with missing follow-up data were censored at the last date they were known to be alive (overall survival), or alive without disease progression.
In both the intensive and non-intensive pathways, disease was assessed after each cycle of induction chemotherapy (before high-dose melphalan and autologous stem-cell transplantation in the intensive pathway), and every 3 months thereafter, with an assessment at 100 days after transplantation in the intensive pathway. Treatment response was monitored centrally at the University of Birmingham, Birmingham, UK, from serum and urine protein and free light-chain studies, or, if results of such studies were missing, by review of local laboratory results in which results were verifi ed by an independent response-assessment panel.
Assessors at the central laboratory were masked with respect to treatment; assessors of local laboratory results
Intensive pathway
Non-intensive pathway had access to treatment allocation information, but such information was not taken into consideration in assessment of response. Responses and disease progression were defi ned according to international response criteria. 19 Briefl y, complete response was defi ned as negative immunofi xation (100% M-protein reduction), and very good partial response was defi ned as at least 90% M-protein reduction with positive immunofi xation. 19 Safety was assessed by continuous monitoring of adverse events. Serum creatinine was monitored monthly during induction chemotherapy and, thereafter, monthly for zoledronic acid and every 3 months for clodronic acid. Serious adverse events were defi ned as treatment emergent if they were judged by the treating physician to be potentially related to study drugs. Data for skeletalrelated events, defi ned as vertebral fractures, other fractures, spinal cord compression, need for radiation or surgery to bone lesions, and new osteolytic bone lesions, were recorded until disease progression.
Statistical analysis
The sample size was calculated on the basis of the comparisons in chemotherapy regimens in the factorial design. In the intensive pathway, we aimed to recruit 1080 patients (540 per group) to test the hypothesis that CTD was not inferior to CVAD, with a hazard ratio (HR) of 1·2 and 80% power at a 5% signifi cance level. In the nonintensive pathway, we aimed to recruit 850 patients (425 per group) to assess whether CTDa was superior to standard chemotherapy with MP, with 80% power at a 5% signifi cance level. We calculated that the sample size for the two pathways combined had suffi cient power (>80%) to detect a reduction of 10% in the proportion of patients with skeletal-related events in patients on zoledronic acid compared with those on clodronic acid.
Analyses were based on the treatments that patients were randomised to receive and the intention-to-treat population, defi ned as all randomised patients with histologically confi rmed multiple myeloma who provided written informed consent. Between-group comparisons for overall survival and progression-free survival were done with Cox regression models stratifi ed by pathway and adjusted for minimisation factors (including treatment centre) and type of induction chemotherapy. Between-group comparisons in overall response rate were assessed with logistic-regression models. We generated a Cox model for skeletal-related events, which included the minimisation factors, chemotherapy, and history of skeletal-related events at baseline (stratifi ed by pathway); this model was used to calculate p values. A post-hoc analysis compared overall survival between patients randomised to receive zoledronic acid versus clodronic acid, with adjustment for time-dependent diff erences in rates of skeletalrelated events.
Cox models were assessed for statistical violations. Adjustment for treatment centre in the Cox models of overall survival and progression-free survival was the only factor identifi ed: a small treatment centre (n=12) reported unfavourable mortality results for patients treated with clodronic acid with a HR of 3·46 versus zoledronic acid. Additional exploratory analyses were done to validate the results when stratifi cation by treatment centre was not included (based on the model violation), and to examine the relative eff ects of zoledronic acid versus clodronic acid during the fi rst few months on the study drug in response to rapid separation of the overall survival curves. Resultant exploratory analyses focused on the fi rst 4 months and included Kaplan-Meier assessments of overall survival and progression-free survival and assessments of early deaths (within the fi rst 120 days on study drug) that were related to treatment or multiple myeloma.
The Kaplan-Meier analyses for overall survival were stratifi ed by intensive versus non-intensive induction chemotherapy, with p values calculated by the log-rank test. HRs for overall and progression-free survival were developed with Cox proportional hazards models, stratifi ed by pathway and adjusted for minimisation factors (treatment centre, haemoglobin, corrected serum calcium, serum creatinine, platelet count, and type of chemotherapy); p values were based on these models. For overall response rate, p values were calculated by logistic regression adjusted for minimisation factors (excluding treatment centre for exploratory post-hoc analyses because few patients were enrolled at some treatment centres) and chemotherapy. For between-group comparisons of adverse events, p values were calculated by Fisher's exact test.
Statistical analyses were done with SAS (version 9.2) and Digital Visual Fortran software (version 6.0A). All tests were two-sided and at the 5% signifi cance level, without adjustment for multiplicity.
This trial is registered, number ISRCTN68454111.
Role of the funding source
None of the funding organisations was involved in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication. All authors had full access to trial data, and the chief investigators had the fi nal responsibility for the decision to submit for publication.
Results
Between May, 2003, and November, 2007, 1970 patients were recruited, of whom 1960 were eligible for analysis by intention to treat (fi gure 1). Demographic and disease characteristics were well balanced between the zoledronic acid and clodronic acid groups at baseline (table 1) .
Patients in the intensive pathway were generally younger and had more aggressive bone disease than did those in the non-intensive pathway. Overall, most patients (about 97%, n=1898) were white, and 71% (n=1401) had myeloma bone disease. By the cutoff date of Oct 5, 2009, most patients remained on treatment until disease progression or the end of the study period (n=746 for zoledronic acid, n=794 for clodronic acid). Median follow-up was 3·7 years (IQR 2·9-4·7), with patients receiving bisphosphonates for a median of 350 days (IQR 137-632) before disease progression (table 2) . Only 14 patients, fi ve on zoledronic acid and nine on clodronic acid, had less than 12 months' follow-up.
Our assumption that the intensity of induction chemotherapy would have no interaction with diff erences in the endpoint of overall survival with zoledronic acid versus clodronic acid was valid (p=0·74 for the intensive pathway, p=0·13 for the non-intensive pathway), enabling the data to be analysed as a factorial trial, as per the Although the study was not powered to detect a signifi cant diff erence between drug groups in the intensive and non-intensive pathways, overall survival was longer with zoledronic acid than with clodronic acid, although not signifi cantly so, in both the intensive (HR 0·84, 95% CI 0·68-1·03; p=0·0854) and non-intensive pathways (0·83, 0·69-1·00; p=0·0492; table 3). Overall, zoledronic acid extended median overall survival by 5·5 months to 50·0 months (IQR 21·0 to not reached) compared with clodronic acid (44·5 months, IQR 16·5 to not reached; fi gure 2A). During the fi rst 4 months of treatment, overall survival curves clearly separated between the drug groups (fi gure 2B). When stratifi cation by treatment centre was omitted, the benefi t of zoledronic acid to overall survival remained signifi cant compared with clodronic acid (HR 0·87, 95% CI 0·77-0·99, p=0·037). For patients in the intensive and non-intensive pathways combined, more early deaths related to treatment regimen or multiple myeloma occurred with clodronic acid than with zoledronic acid (p=0·0008; table 4). During this time, signifi cantly fewer patients on zoledronic acid had died of renal failure (p<0·0001), and fewer had died of infection, although the diff erence was not signifi cant (p=0·08), than did those on clodronic acid (table 4) .
Zoledronic acid signifi cantly improved progressionfree survival by 12% (fi gure 3), and extended median progression-free survival by 2·0 months to 19·5 months (IQR 9·0-38·0) compared with clodronic acid (17·5 months, IQR 8·5-34·0). Although the diff erence between drug groups was not signifi cant for the full follow-up period (fi gure 2C), early separation was recorded between the progression-free survival curves (fi gure 2D). Progression-free survival was non-signifi cantly extended with zoledronic acid as compared with clodronic acid in both the intensive (HR 0·90, 95% CI 0·78-1·05) and nonintensive pathways (0·87, 0·74-1·01). We did not record any signifi cant interactions between the four regimens of fi rst-line bisphosphonate treatment plus induction chemotherapy and the diff erences in overall and progression-free survival with zoledronic acid versus clodronic acid. 611 patients had a skeletal-related event before disease progression (27% [265/981] on zoledronic acid; 35% [346/979] on clodronic acid; p=0·0004). In an exploratory analysis, we generated a Cox model including fi rst skeletal-related event as a time-dependent covariate, which showed that improvement in overall survival with zoledronic acid versus clodronic acid remained signifi cant (HR 0·85, 95% CI 0·74-0·97; p=0·018).
Overall response rates were higher with intensive than with non-intensive induction chemotherapy, irrespective of bisphosphonate treatment (table 5) . 19 For non-intensive therapy, zoledronic acid had a signifi cantly increased rate of complete or very good partial response, and had a higher rate of complete response than did clodronic acid, although the diff erence was not signifi cant. For intensive therapy, rates of complete or very good partial response were not signifi cantly diff erent between drug groups.
The profi le of adverse events was as expected for patients with multiple myeloma receiving bisphosphonate treatment plus induction chemotherapy (table 6) . Occurrence of most adverse events was similar between the zoledronic acid and clodronic acid groups in both the intensive and non-intensive pathways. Overall, although more patients on zoledronic acid than on clodronic acid had serious adverse events, rates of treatment-emergent serious adverse events did not diff er signifi cantly between these drug groups. Of the treatment-emergent serious adverse events, signifi cantly more patients on zoledronic acid developed bone and musculoskeletal disorders than did those on clodronic acid, and a lower rate of infections was recorded in the zoledronic acid group, but the diff erence was not signifi cant. Both fi ndings might be related to immunesystem activation during an acute-phase reaction.
Rates of acute renal failure were low and similar for patients treated with zoledronic acid and clodronic acid in both the intensive and non-intensive pathways (table 6) . Thromboembolic events were more common in the intensive pathway than in the non-intensive pathway, which was most probably caused by the administration of induction chemotherapy. Although thromboembolic events were more common in the overall population of patients on zoledronic acid than in those on clodronic acid, rates were not signifi cantly diff erent in each pathway separately. Confi rmed osteonecrosis of the jaw was uncommon, but rates were higher for zoledronic acid than for clodronic acid (4% [35/983] vs <1% [3/979]; table 6). Recovery data for osteonecrosis of the jaw were available for nine patients on zoledronic acid and one on clodronic acid, and showed complete healing for three Skin and subcutaneous disorders 6 (1%) 3 (1%) 0·34 4 (1%) 6 (1%) 0·54 1·0
*p value for comparison of zoledronic acid (n=983) versus clodronic acid (n=979). †Two patients on zoledronic acid who were excluded from the non-intensive pathway because no consent was received were included in the safety population. ‡Irrespective of suspected association with study drugs; patients who had more than one type of adverse event have been listed against all relevant types of events, but patients who had more than one occurrence of the same type of event are recorded only once. §Suspected association with study drugs. patients on zoledronic acid, improvement for two patients on zoledronic acid, and no change for four patients on zoledronic acid and one patient on clodronic acid. Dental surgery or trauma was known to precede osteonecrosis of the jaw in six patients on zoledronic acid.
Discussion
Bisphosphonates are the standard of care for prevention of skeletal-related events and treatment of hypercalcaemia in patients with advanced cancer. 1, 3 In this large-scale, randomised trial of bisphosphonates in addition to standard induction chemotherapy for multiple myeloma, zoledronic acid was superior to clodronic acid across several endpoints. Zoledronic acid signifi cantly improved overall survival and progression-free survival, with extension of overall survival by 5·5 months and progression-free survival by 2·0 months, and signifi cantly reduced the proportion of patients with a skeletal-related event. Moreover, zoledronic acid improved overall survival independently of the reduction in skeletal-related events, suggesting that the drug has underlying antimyeloma eff ects, which is consistent with higher (albeit not statistically signifi cantly so) overall response rates in patients on zoledronic acid than in those on clodronic acid. Indeed, Child and colleagues established that response to induction chemotherapy for multiple myeloma signifi cantly correlates with overall survival. 20 Diff erences in overall survival between the zoledronic acid and clodronic acid groups emerged within the fi rst few months of treatment, supporting possible synergy of zoledronic acid with fi rstline myeloma therapies or improved antimyeloma eff ects of zoledronic acid when used early in the disease course.
Although improvements in disease outcomes with zoledronic acid are consistent with results from small controlled studies of zoledronic acid in newly diagnosed multiple myeloma (n=94) or early stage multiple myeloma (n=140), 21, 22 zoledronic acid had no significant benefi ts to disease outcome in asymptomatic myeloma (n=163). 23 This discrepancy is probably attributable to reduced risk of disease progression in asymptomatic disease and decreased statistical power with endpoints for disease outcomes. Indeed, most guidelines do not recommend bisphosphonates for smouldering myeloma because this disease has a fairly indolent nature. 24, 25 Additionally, most patients in our trial continued to receive bisphosphonate therapy until disease progression whereas, in other studies, the duration of bisphosphonate treatment with respect to disease course is uncertain.
Although existing practice at research institutes participating in our trial is to treat with bisphosphonates at least until disease progression, the optimal duration of bisphosphonate treatment needs further analysis. Society treatment guidelines are inconsistent with regard to the optimal duration of bisphosphonate therapy, especially in patients with overall disease remission. 3, 26 Indeed, in a study of maintenance therapy in patients who did not have disease progression within the fi rst 2 months after autologous stem-cell transplantation (n=597), pamidronic acid did not improve event-free survival or overall survival versus no maintenance, whereas the combination of pamidronic acid and thalidomide improved both outcomes compared with no treatment or pamidronic acid alone. 27 In our study, although the benefi ts to overall survival of zoledronic acid versus clodronic acid were most pronounced early in the study, the overall survival curves separated throughout the study, suggesting potential for continuing benefi t.
We used clodronic acid and zoledronic acid in our study because both are approved in the UK for prevention of skeletal-related events in multiple myeloma. Although zoledronic acid and clodronic acid are licensed for malignant bone lesions, not all patients had detectable bone disease at study entry. However, because bone lesions develop in virtually all patients during the disease course, bisphosphonate therapy was given to all patients. Although MRC Myeloma IX is not a placebo-controlled trial, the patterns of skeletal-related events were consistent with those in previous placebocontrolled studies in multiple myeloma-eg, in Berenson and colleagues' trial, 9 44% of patients on placebo and 28% of those on pamidronic acid had a skeletal-related event within 1 year. Similarly, in the 25-month randomised trial of pamidronic acid versus zoledronic acid, 12, 28 Rosen and colleagues reported skeletal-related events in 47% of patients on zoledronic acid versus 49% of those on pamidronic acid at 13 months' follow-up (a duration similar to the median time on study drug in our trial).
All intravenous bisphosphonates are associated with eff ects on renal function that are dependent on dose and rate of infusion. 29 Our study adhered strictly to the renal safety protocols specifi ed in prescription information for zoledronic acid. The risk of renal failure was not signifi cantly diff erent between zoledronic acid and clodronic acid, despite use of thalidomide, a potentially nephrotoxic agent. This fi nding is consistent with a report by Spencer and colleagues, 30 in which renal safety profi les did not diff er signifi cantly between zoledronic acid alone and zoledronic acid plus thalidomide in patients with multiple myeloma who were receiving maintenance therapy after autologous stem-cell transplantation. In our study, thromboembolic events were more common in the zoledronic acid group than in the clodronic acid group in both the intensive and nonintensive pathways, but diff erences were not signifi cant. Further analyses of confounding variables (eg, indwellingcatheter use) are needed to assess these diff erences fully.
Our study provides important prospective data on occurrence of osteonecrosis of the jaw in patients with multiple myeloma, with adherence to best practice throughout the study. Although osteonecrosis of the jaw was more common in patients on zoledronic acid than in those on clodronic acid, the rates compare favourably with those summarised in guidelines from the American Society of Clinical Oncology for bisphosphonate use in multiple myeloma, 26 and most events were manageable and of low grade. According to reports in 2008-09, risk of osteonecrosis of the jaw can be further mitigated with dental hygiene programmes before start of bisphosphonates, and by use of prophylactic antibiotic therapy for oral surgery during bisphosphonate treatment. [31] [32] [33] Implementation of such procedures might further reduce risk of osteonecrosis of the jaw in all patients, and might have prevented some of the events recorded in our trial.
As with most large trials, the MRC Myeloma IX trial does not provide defi nitive answers to all the questions it sought to address. The regimens and practices common at the start of the study have since developed. Nonetheless, the study drugs were integrated into the latest chemotherapy regimens, which remain cornerstones of antimyeloma therapy. Because the trial was designed to compare several treatment options, some statistically signifi cant eff ects could have been chance fi ndings. However, we believe that our fi ndings are robust because signifi cant diff erences in the main fi ndings had low p values, and we used in-depth and comprehensive statistical models and analyses, such as exploratory analyses showing a signifi cant benefi t to overall survival with zoledronic acid during the fi rst 4 months. Another limitation of any study of oral therapies is the potential for poor compliance. We are not able to distinguish the eff ects of poor compliance in our study from the inherently lower effi cacy of the oral bisphosphonate clodronic acid versus zoledronic acid. However, clinically the end result is the same, supporting preferential use of zoledronic acid. The intravenous bisphosphonate pamidronic acid, a bisphosphonate with antiresorptive activity intermediate between clodronic acid and zoledronic acid, 4 is also approved for prevention of skeletal-related events in this setting. Therefore, the MRC Myeloma IX trial leaves several questions unanswered, including whether pamidronic acid might also off er benefi ts to progression-free survival and overall survival versus clodronic acid.
Adverse events in our trial were consistent with the established tolerability profi les of zoledronic acid and clodronic acid in multiple myeloma. One exception was that renal adverse events occurred at a similar rate for both bisphosphonates, despite the fact that one drug was given orally and the other intravenously, suggesting that the aetiology of these events could stem from the underlying disease. Indeed, fewer early deaths from renal failure occurred in the zoledronic acid group than in the clodronic acid group.
The improvement in overall survival with zoledronic acid remained signifi cant after adjustment for the reduction in risk of skeletal-related events. These data add to growing clinical evidence supporting anticancer benefi ts with zoledronic acid in patients with newly diagnosed cancers. 14, 21 According to preclinical studies of zoledronic acid, this improvement could occur via several potential mechanisms of action, including proapoptotic eff ects on cancer cells, cytotoxic synergy with chemotherapeutic agents, antiangiogenesis, interference with adhesion of cancer cells, and stimulation of host anticancer immune responses. 4, 7, 8 The improvements in complete or very good partial response in our trial support synergy between zoledronic acid and induction therapy. Although we have not defi nitively identifi ed the underlying mechanism of action, the early improvement in overall survival with zoledronic acid compared with clodronic acid supports early use of zoledronic acid in multiple myeloma.
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